FDA panel endorses decision on Avastin

An advisory panel to the US Food and Drug Administration has endorsed the agency’s decision in late 2010 to remove the breast cancer indication for Avastin (bevacizumab) despite strenuous objections from the drug’s manufacturer, Roche.